Avidity Biosciences/RNA

$27.39

2.93%
-
1D1W1MYTD1YMAX

About Avidity Biosciences

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Ticker

RNA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sarah Boyce

Employees

253

Headquarters

San diego, United States

RNA Metrics

BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$2.95
EPS
0.80
Beta
-
Dividend rate
$2.5B
0.80121
$30.84
$4.83
1.2M
12.467
-29.22%
-32.91%
-31.71%
231.569
3.028
3.029
12.5%
12.24%
12.1%

What the Analysts think about RNA

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
65.21% upside
High $66.00
Low $33.00
$27.39
Current price
$45.25
Average price target

RNA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,965.71% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.5M
66.67%
Net income
-$69M
13.91%
Profit margin
-1,965.71%
-31.66%

RNA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.71
-$0.79
-$0.79
-
Expected
-$0.80
-$0.77
-$0.66
-$0.78
-$0.78
Surprise
-17.38%
-7.55%
19.7%
1.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Avidity Biosciences stock?

Avidity Biosciences (RNA) has a market cap of $2.5B as of May 30, 2024.

What is the P/E ratio for Avidity Biosciences stock?

The price to earnings (P/E) ratio for Avidity Biosciences (RNA) stock is 0 as of May 30, 2024.

Does Avidity Biosciences stock pay dividends?

No, Avidity Biosciences (RNA) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Avidity Biosciences dividend payment date?

Avidity Biosciences (RNA) stock does not pay dividends to its shareholders.

What is the beta indicator for Avidity Biosciences?

Avidity Biosciences (RNA) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Avidity Biosciences stock price target?

The target price for Avidity Biosciences (RNA) stock is $45.25, which is 65.21% above the current price of $27.39. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Avidity Biosciences stock

Buy or sell Avidity Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing